Showing papers by "Lorenz Trümper published in 2013"
TL;DR: A combined immunohistochemistry or FISH/immunohistochemical score predicts outcome in DLBCL patients independent of the IPI and identifies a subset of 15% of patients with dismal prognosis in the high-risk IPI group following treatment with R-CHOP.
467 citations
TL;DR: A recurrent pattern of secondary genetic alterations in IRF4 translocation‐positive lymphomas is unraveled, finding no recurrent copy‐neutral losses of heterozygosity.
Abstract: Translocations affecting chromosome subband 6p25.3 containing the IRF4 gene have been recently described as characteristic alterations in a molecularly distinct subset of germinal center B-cell-derived lymphomas. Secondary changes have yet only been described in few of these lymphomas. Here, we performed array-comparative genomic hybridization and molecular inversion probe microarray analyses on DNA from 12 formalin-fixed paraffin-embedded and two fresh-frozen IRF4 translocation-positive lymphomas, which together with the previously published data on nine cases allowed the extension of copy number analyses to a total of 23 of these lymphomas. All except one case carried chromosomal imbalances, most frequently gains in Xq28, 11q22.3-qter, and 7q32.1-qter and losses in 6q13-16.1, 15q14-22.31, and 17p. No recurrent copy-neutral losses of heterozygosity were observed. TP53 point mutations were detected in three of six cases with loss of 17p. Overall this study unravels a recurrent pattern of secondary genetic alterations in IRF4 translocation-positive lymphomas.
29 citations
TL;DR: It is demonstrated that CD34+ PB FISH correlates significantly with CCB analysis and represents a feasible method for a reliable non-invasive cytogenetic monitoring from PB.
18 citations
TL;DR: This study provides further evidence that proximal IL-10 promoter gene variations are associated with clinical course of patients with HL, supporting the need to design studies focusing on identification of predictors to reduce the side effects of therapy.
Abstract: Background.
Hodgkin lymphoma (HL) is a lymphoid malignancy characterized by the production of various cytokines possibly involved in immune deregulation. Interleukin-10 (IL-10) serum levels have been associated with clinical outcome in patients with HL. Because host genetic variations are known to alter the expression and function of cytokines and their receptors, we investigated whether genetic variations influence clinical outcome of patients with HL.
14 citations
TL;DR: This data indicates that once-weekly dosing with anthracycline-based multiagent chemotherapy regimens for MTCL or systemic anaplastic large cell lymphoma is a viable treatment option for these patients with high response rates.
Abstract: TPS8605 Background: MTCL including systemic anaplastic large cell lymphoma (sALCL) are aggressive neoplasms. Anthracycline-based multiagent chemotherapy regimens have demonstrated response rates ra...
8 citations
TL;DR: Dieser Fragestellung geht unter anderem die CLL12-Studie nach, bei der Patienten mit Binet-Stadium A, die nach biologischen and genetischen Parametern ein hohes oder sehr hohes Rezidivrisiko haben, behandelt werden.
Abstract: sich die Therapie richtet. Komorbiditäten und Patientenalter sind in den Hintergrund gerückt. Die therapeutische Inhibition des B-Zell-Rezeptor-abhängigen Signalweges hat sich in den letzten Studien bei Patienten in fortgeschrittenen Stadien als so potent erwiesen, dass die CLL-Studiengruppe nun auch untersuchen wird, ob die Tyrosinkinase-Inhibition und die Unterbrechung des Signalweges auch bei Patienten mit Binet-Stadium A die Erkrankung stoppen kann. Dieser Fragestellung geht unter anderem die CLL12-Studie nach, bei der Patienten mit Binet-Stadium A, die nach biologischen und genetischen Parametern ein hohes oder sehr hohes Rezidivrisiko haben, behandelt werden. Bei den anderen Patienten mit Stadium A gilt weiterhin die Strategie «Watch and Wait». Ein neuer prognostischer Rezidivrisiko-Score, der das individuelle Risiko der Patienten voraussagen soll, wird zurzeit international erarbeitet. Das Risiko für einen schweren Krankheitsverlauf erhöhen vor allem die 17pund die 11q-Deletion.
2 citations
TL;DR: Retroperitoneal fibrosis as manifestation of chronic GVHD after allogeneic hematopoietic SCT is described.
Abstract: Retroperitoneal fibrosis as manifestation of chronic GVHD after allogeneic hematopoietic SCT
1 citations
TL;DR: Rearrangements of MYC and BCL2 seem to be relevant prognostic factors also in young high-risk patients, and it seems unlikely that the rearrangements described here (completely) explain the poor prognosis of young, high- risk patients.
1 citations
TL;DR: This poster presents a poster presented at the 2016 China oncology congress of the American Association for the Advance Study of Oncology (AAS) entitled “Advances in Radiology and Pathology: Foundations of Post-operative Care Quality Assurance and Efficacy”.
Abstract: Cecilia Y S Ho Alex W H Ng Janet F Y Lee Anthony W I Lo Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, State Key Laboratory in Oncology in South China, The Chinese University of Hong Kong, Department of Imaging and Interventional Radiology, The Chinese University of Hong Kong, and Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong
1 citations